You are here

  • Home
  • Archive
  • Volume 14, Issue 10
  • Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial

Citation Tools

Article menu
Respiratory medicine
Original research
Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
O'Hara DV, Bassi A, Wilcox A, et al
Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial
BMJ Open 2024;14:e081790. doi: 10.1136/bmjopen-2023-081790